JAC Advance Access originally published online on April 21, 2009
Journal of Antimicrobial Chemotherapy 2009 64(1):200-205; doi:10.1093/jac/dkp135
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original research |
European Surveillance of Antimicrobial Consumption (ESAC): outpatient parenteral antibiotic treatment in Europe
1 Department of General Practice, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium 2 Research Foundation—Flanders, Brussels, Belgium 3 Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium 4 Unit of Epidemiology, Scientific Institute of Public Health, Brussels, Belgium
Received 25 February 2009; accepted 23 March 2009
* Corresponding author. Department of General Practice, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium. Tel: +32-3-820-2525; Fax: +32-3-820-2526; E-mail: samuel.coenen{at}ua.ac.be
Objectives: To assess the proportion of parenteral treatment of the total outpatient antibiotic use in Europe, and to identify the antibiotic groups and individual antibiotics most commonly administered in this way.
Methods: Within the European Surveillance of Antimicrobial Consumption (ESAC; www.esac.ua.ac.be), using the anatomic therapeutic chemical (ATC) and defined daily dose (DDD) classification, data on outpatient use of antibacterials for systemic use (ATC J01), aggregated at the level of the active substance and expressed in DDD per 1000 inhabitants per day (DID; WHO version 2007), were extracted for 2006 by route of administration and by country. Parenteral use was expressed as a percentage of the total outpatient use in DID.
Results: In 20 European countries, the total outpatient antibiotic use ranged from 27.91 DID in France to 9.58 DID in Russia. The proportion of outpatient parenteral antibiotic treatment ranged from 6.75% in Russia to 0.001% in Iceland. The three most commonly used antibiotic groups for parenteral treatment in Europe were the cephalosporins (J01D; 44.58%), the aminoglycosides (J01G; 25.27%) and the penicillins (J01C; 17.78%). Four antibiotics [gentamicin (J01GB03) 18.53%; ceftriaxone (J01DD04) 17.85%; cefazolin (J01DB04) 13.16%; and lincomycin (J01FF02) 5.47%] represented more than half of the use.
Conclusions: In all 20 European countries studied together, 2.04% of outpatient antibiotics were used for parenteral treatment. However, as for the total outpatient antibiotic use and the use of different antibiotic groups and antibiotics, there is a striking variation in the proportions of parenteral antibiotic use in Europe. More in-depth data on outpatient antibiotic use are needed to explain this variation.
Keywords: antibiotic use , route of administration , drug consumption , pharmacoepidemiology , ambulatory care
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Adriaenssens, H. Goossens, S. Coenen, and on behalf of the ESAC Project Group Comment on: Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin J. Antimicrob. Chemother., October 19, 2009; (2009) dkp379v1. [Full Text] [PDF]
|
|
|
|
|
|
D. Morris, F. Boyle, V. Buckley, L. Xu, B. Hanahoe, P. Hawkey, and M. Cormican CTX-M enzymes are the predominant extended-spectrum {beta}-lactamases produced by Enterobacteriaceae in Ireland J. Antimicrob. Chemother., October 1, 2009; 64(4): 864 - 866. [Full Text] [PDF]
|
|